Le Lézard
Classified in: Health
Subjects: CCA, ACC

Invitation - Presentation of Sobi's Q2 2018 Results


STOCKHOLM, July 2, 2018 /PRNewswire/ -- On 18 July, at 08:00 CET, Swedish Orphan Biovitrum AB (publ) (Sobitm) will publish its report for the second quarter 2018.

Financial analysts and media are invited to participate in a telephone conference, which will include a presentation of the results, on the same day at 14:00 CET. The event will be hosted by Sobi's CEO and President, Guido Oelkers, and the presentation will be held in English.

The presentation can be followed live, or afterwards on www.sobi.com. Slides used in the presentation will be made available on Sobi's website prior to the telephone conference.

To participate in the telephone conference, please call:
SE: +46-8-566-42-697
UK: +44-203-008-98-09
US: +1-855-753-22-36 

Click here to go to the live webcast.

After the live event the webcast will be available on-demand via the same URL.

About Sobitm

Sobitm is an international speciality healthcare company dedicated to rare diseases. Our vision is to be recognised as a global leader in providing access to innovative treatments that transform lives for individuals with rare diseases. The product portfolio is primarily focused on treatments in Haemophilia and Specialty Care. Partnering in the development and commercialisation of products in specialty care is a key element of our strategy. Sobi has pioneered in biotechnology with world-class capabilities in protein biochemistry and biologics manufacturing. In 2017, Sobi had total revenues of SEK 6.5 billion and approximately 850 employees. The share (STO:SOBI) is listed on Nasdaq Stockholm. More information is available at www.sobi.com.

For more information please contact:

Media relations
Linda Holmström,
Senior Communications Manager
+46-708-734-095
[email protected]  



Investor relations
Jörgen Winroth,
Vice President,
Head of Investor Relations
+1-347-224-0819,
+1-212-579-0506
[email protected]

 

This information was brought to you by Cision http://news.cision.com

http://news.cision.com/swedish-orphan-biovitrum-ab/r/invitation---presentation-of-sobi-s-q2-2018-results,c2565991

The following files are available for download:

http://mb.cision.com/Main/14266/2565991/871430.pdf

PDF

SOURCE Swedish Orphan Biovitrum AB


These press releases may also interest you

at 07:28
BioArctic AB (publ) today announced that BioArctic AB and Eisai Co., Ltd., have entered into a research evaluation agreement regarding BAN2802, a potential new treatment combining BioArctic's proprietary BrainTransportertm technology with an...

at 07:00
LifeLabs workers from Orillia, Barrie, Collingwood, and Wasaga Beach will rally with community members and allies ahead of their imminent strike deadline. They stand firm in their demands for a fair contract that puts patients and workers before...

19 avr 2024
Remedium Healthcare Products is proud to announce the launch of NuVeria Labs' revolutionary Sacral Silicone Dressing, now available for purchase on Amazon, bringing advanced wound care solutions directly to consumers' doorsteps. Designed to address...

19 avr 2024
Getting specialty medications into...

19 avr 2024
Arthrex, a global leader in minimally invasive surgical technology, has once again taken home prestigious medals for product innovation at the 37th annual Edison Awards. "This product, along with our other innovations,...

19 avr 2024
Aligned with the trend of immersive water therapy in 2024, Baros Maldives' Serenity Spa stands out as an oasis of indulgent spa and beauty rituals, boasting a 50-year legacy of luxury. Nestled within a tranquil sanctuary amidst the lush Maldivian...



News published on and distributed by: